Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This refers to a specific topical anesthetic cream formulation containing 7% lidocaine and 7% tetracaine (LTTA) studied by Northwestern University for the management of procedural pain. The drug is a combination of an amide-type local anesthetic (lidocaine) and an ester-type local anesthetic (tetracaine), both of which function by reversibly blocking voltage-gated sodium channels in neuronal membranes. This blockade prevents the initiation and conduction of nerve impulses, providing localized anesthesia. In clinical research (IRB # STU00200401), this high-concentration formulation was evaluated for its efficacy in reducing pain during dermatologic laser procedures, such as Q-switched 532nm laser treatment for lentigines, comparing it against standard 2.5% lidocaine/2.5% prilocaine cream and placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine 7% + tetracaine 7% cream.